

The Effect of Menopausal Status, Age, and Human Immunodeficiency Virus (HIV) on Non-AIDS Comorbidity Burden Among US Women

Lauren F. Collins,^{1,2} C. Christina Mehta,¹ Frank J. Palella Jr.,³ Yetunde Fatade,⁴ Susanna Naggie,⁵ Elizabeth T. Golub,⁶ Kathryn Anastos,⁷ Audrey L. French,⁸ Seble Kassaye,⁹ Tonya N. Taylor,¹⁰ Margaret A. Fischl,¹¹ Adaora A. Adimora,¹² Mirjam-Colette Kempf,¹³ Phyllis C. Tien,^{14,15} Anandi N. Sheth,^{1,2} and Ighovwerha Ofotokun^{1,2}

¹Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA; ²Grady Healthcare System, Infectious Diseases Program, Atlanta, Georgia, USA;

³Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; ⁴Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA; ⁵Duke Clinical Research Institute and Duke University School of Medicine, Durham, North Carolina, USA; ⁶Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; ⁷Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA; ⁸Division of Infectious Diseases, CORE Center, Stroger Hospital of Cook County, Chicago, Illinois, USA;

⁹Georgetown University Medical Center, Washington, DC, USA; ¹⁰SUNY Downstate Health Sciences University, Brooklyn, New York, USA; ¹¹Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA; ¹²School of Medicine and UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; ¹³Schools of Nursing, Public Health, and Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; ¹⁴Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA; and ¹⁵Medical Service, Department of Veterans Affairs, San Francisco, California, USA

Menopause may impact the earlier onset of aging-related comorbidities among women with versus without human immunodeficiency virus (HIV). We found that menopausal status, age, and HIV were independently associated with higher comorbidity burden, and that HIV impacted burden most in the pre-/perimenopausal phases.

Keywords. women with HIV; HIV and aging; HIV and menopause; non-AIDS comorbidities; comorbidity burden.

Women with human immunodeficiency virus (HIV) (WWH) are living longer and an increasing number are reaching menopause. From 2014 to 2018, HIV diagnoses increased by 5% among women aged 55 years and older [1]. In this growing population of aging WWH, unique biological and psychosocial factors may affect the senescence process, including the menopausal transition and development of non-AIDS comorbidities (NACMs).

Menopause is characterized by estrogen depletion, resulting from aging-related declines in ovarian reserve, and is associated with an increased risk of cardiovascular disease (CVD), osteoporosis, and other NACMs [2]. Women with HIV may experience menopause earlier and with greater symptom intensity than the general female population; however, studies are inconsistent and inconclusive [3]. HIV-related inflammatory effects on the neuroendocrine axis have the potential to impact menopause timing and severity [4, 5]. Further, the menopausal transition among WWH may also be affected by antiretroviral exposure and a high prevalence of substance use, viral coinfections, and socioeconomic hardship in this population [6].

Leveraging the Women's Interagency HIV Study (WIHS), we previously showed that WWH versus women without HIV had a higher burden of 10 aging-related NACMs overall and specifically among those aged 40–49 and 60 years and older, and had a significantly earlier incidence of NACMs [7, 8]. Mechanisms by which menopause may affect the natural history of aging-related NACMs among WWH remain largely unknown; thus, we evaluated whether HIV modifies the effects of age and menopausal status on comorbidity burden.

METHODS

We analyzed data from the WIHS, the largest prospective, multisite US cohort of women with and without HIV. Participants underwent semiannual in-depth assessment of medical history, physical examination, and biospecimen collection [7]. Focusing on the menopausal transition, we included women aged 26–59 years with 2 or more study visits from 2009 (when >80% of WWH used antiretroviral therapy) through the end of observation (30 March 2018).

The primary outcome was comorbidity burden, defined as the number of prevalent NACMs per participant as of the last observation out of 10 total assessed (hypertension, dyslipidemia, diabetes, non-AIDS cancer, psychiatric illness, cardiovascular, kidney, lung, liver, and bone disease). Non-AIDS comorbidities were ascertained using up to 3 data sources: (1) self-reported diagnosis or medication, (2) clinical measurement, and/or (3) laboratory evidence, as previously described [7]. At last observation, participants were categorized by age (<40, 40–49, 50–59 years) and by menopausal status based on participant responses to detailed questions on menstrual cycles (ie, regularity and timing of periods) according to the Stages of Reproductive Aging Workshop (STRAW) +10 principal criteria as premenopausal (ie, reproductive), perimenopausal (ie, menopausal transition characterized by irregular menstrual cycles), or postmenopausal (ie, beginning the day after no menstrual period in >12 months) [9]. Among those who

Received 01 June 2022; editorial decision 31 May 2022; published online 10 June 2022

Correspondence: L. F. Collins, Infectious Diseases, Emory University School of Medicine, 49 Jesse Hill Jr Drive SE, Atlanta, GA 30303 (lauren.frances.collins@emory.edu)

Clinical Infectious Diseases® 2023;76(3):e755–e8

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

https://doi.org/10.1093/cid/ciac465

were postmenopausal, surgical menopause was ascertained by participant-reported bilateral oophorectomy. HIV serostatus was determined at study entry and, if negative, at each subsequent visit; seroconverters were excluded.

Linear regression evaluated the effects of HIV serostatus, categorized age, and menopausal status on prevalent comorbidity burden. Model 1 (unadjusted) included these terms plus all possible interaction terms derived from the HIV \times age \times menopausal status 3-way interaction. To incorporate potential confounders of menopausal status on comorbidity burden, model 2 (covariate-adjusted) included all model 1 variables plus race (non-Hispanic Black or White, Hispanic, other), body mass index (BMI; ≥ 30 or < 30 kg/m²), and smoking status (current, former, never) at last observation.

RESULTS

Among 2716 women (1931 WWH; 785 without HIV), the median age was 48 (quartile [Q] 1–Q3, 41–54) years, 65% were non-Hispanic Black, 51% had a BMI of 30 kg/m² or greater, and 38% reported current smoking at last observation. Hormonal contraceptive or hormone replacement therapy use as of last observation was reported in 5.6% and 2.7% of women, respectively. Overall, 923 (34%) women were premenopausal, 411 (15%) perimenopausal, and 1382 (51%) postmenopausal. Of postmenopausal women, 303 (22%) reported surgical menopause including 7, 71, and 225 participants aged less than 40, 40–49, and 50–59 years, respectively. Mean (standard deviation) NACM burden was 3.1 (2.0) among all women and increased significantly across pre- versus peri- versus postmenopausal women (1.9 [1.5] vs 2.9 [1.9] vs 3.9 [2.0], respectively; $P < .0001$).

The prevalence of postmenopausal status increased with each successive age group, comprising 9% (44/517), 30% (295/978), and 85% (1043/1221) of women aged less than 40, 40–49, and 50–59 years, respectively. Comparing WWH with women without HIV, postmenopausal status was 10% versus 6% ($P = .0939$), 34% versus 21% ($P = .0004$), and 86% versus 85% ($P = .9706$) among women aged less than 40, 40–49, and 50–59 years, respectively. In an unadjusted model, HIV did not significantly modify the effects of age and menopausal status on prevalent comorbidity burden (3-way interaction, $P = .5999$).

In covariate-adjusted analyses, menopausal status, age, and HIV were independently associated with higher comorbidity burden. The estimated mean (95% confidence interval [CI]) NACM burden among pre-, peri-, and postmenopausal women overall was 2.26 (2.03–2.48), 2.83 (2.62–3.04), and 3.41 (3.18–3.65), respectively, and was higher in successive age groups. Across all age and menopause strata, the estimated mean difference (95% CI) in NACM burden was +.32 (.08–.56) comparing women with versus without HIV, and

across all age and HIV strata was +.57 (.29–.86) or +1.16 (.86–1.46) comparing peri- or postmenopausal with premenopausal women, respectively.

Comparing WWH with women without HIV, the estimated mean difference (95% CI) in NACM burden stratified by age less than 40, 40–49, and 50–59 years was +.22 (–.13 to .58), +.50 (.18–.84), and +.52 (–.60 to 1.63) among premenopausal women; +.52 (–.26 to 1.31), +.43 (–.10 to .95), and +.47 (–.22 to 1.17) among perimenopausal women; and –.22 (–1.39 to .95), +0.25 (–.25 to 0.75), and +.18 (–.07 to .43) among postmenopausal women, respectively (Table 1; adjusted 3-way interaction, $P = .9580$).

DISCUSSION

In this hypothesis-generating analysis of a diverse cohort of US women with and without HIV, we observed that menopausal status, age, and HIV were independently associated with a higher burden of NACMs. While HIV did not significantly modify the effects of menopausal status and age on prevalent comorbidity burden, there were trends toward a higher burden of NACMs among WWH versus women without HIV, especially for perimenopausal women aged less than 40 years and pre- and perimenopausal women aged 40–59 years. These findings, if confirmed in larger studies, would have important clinical implications for optimizing NACM screening and prevention strategies for aging WWH.

We previously demonstrated that the burden of aging-related NACMs was significantly higher among WWH versus women without HIV, and that HIV may accelerate comorbidity development beginning in the third decade of life [7, 8]. The current analysis builds on these findings to suggest that the disparate NACM burden occurring among WWH may concentrate more in the pre- and perimenopausal phases than in the postmenopausal period. We also observed that postmenopausal status was more common among WWH than women without HIV younger than 50 years old, corroborating other studies reporting earlier menopause in HIV [3] and suggesting a potentially compounded risk of premature multimorbidity among WWH. Our data suggest that the impact of menopausal status on NACM burden may be greater than the impact of HIV (Table 1), thus underscoring menopause as a key research priority area for aging women.

The menopausal transition is increasingly recognized as an event with substantial biopsychosocial effects on a woman's health and disease trajectory. Longitudinal CVD studies have suggested that cardiometabolic changes occurring during menopause may be intensified beyond chronological aging, highlighting the menopausal transition as a critical window for CVD risk assessment in women [2]. In disentangling the effects of chronological versus reproductive aging among WWH, it is important to consider that HIV-specific virologic,

Table 1. Estimated Mean Non-AIDS Comorbidity Burden at Last Observation in the Women's Interagency HIV Study by HIV Serostatus, Age, Menopausal Status Adjusted for Race, Body Mass Index, and Smoking Status

Age	HIV Serostatus	Sample Size (Pre-, Peri-, Postmenopausal), n	Estimated Mean NACM Burden (95% CI)			P
			Premenopausal (n = 923)	Perimenopausal (n = 411)	Postmenopausal (n = 1382)	
<40 years	Women with HIV	241, 40, 32	1.89 (1.64, 2.13)	2.33 (1.79, 2.88)	2.48 (1.87, 3.09)	.0687
	Women without HIV	156 36, 12	1.66 (1.37, 1.95)	1.81 (1.23, 2.38)	2.70 (1.69, 3.71)	.0519
40–49 years	Women with HIV	318, 144, 235	2.56 (2.35, 2.77)	3.32 (3.03, 3.61)	3.57 (3.32, 3.81)	<.0001
	Women without HIV	160, 61, 60	2.06 (1.76, 2.35)	2.89 (2.44, 3.34)	3.32 (2.86, 3.77)	<.0001
50–59 years	Women with HIV	36, 97, 788	2.95 (2.38, 3.52)	3.56 (3.20, 3.92)	4.30 (4.15, 4.46)	<.0001
	Women without HIV	12, 33, 255	2.43 (1.46, 3.40)	3.09 (2.48, 3.69)	4.12 (3.89, 4.36)	.0008

Linear regression was performed for NACM burden with HIV serostatus, categorized age, menopausal status, and all interaction terms included in the model, as well as race, body mass index, and smoking status: age, $P < .0001$; HIV serostatus, $P = .0083$; menopausal status, $P < .0001$; race, $P < .0001$; body mass index, $P < .0001$; smoking status, $P < .0001$; age \times HIV, $P = .7275$; age \times menopausal status, $P = .0722$; menopausal status \times HIV, $P = .3522$; HIV \times age \times menopausal status, $P = .9580$.

Abbreviations: HIV, human immunodeficiency virus; NACM, non-AIDS comorbidity.

immunologic, and sociobehavioral factors likely influence both processes [10]. Younger age at final menstrual period has been associated with smoking, chronic HCV, HIV-1 viremia, and prior clinical AIDS [4]. These findings, along with our current and prior data [7, 8], suggest that both HIV-related and traditional risk factors impact the menopausal transition and associated NACM risk.

Importantly, menopausal status as ascertained by existing tools (eg, the STRAW +10 or the Study of Women's Health Across the Nation [SWAN] criteria, etc) may inadequately capture the unique sociobiological experience of aging WWH. Ovarian reserve, assessed by anti-Müllerian hormone (AMH) levels, has been shown to be reduced among premenopausal WWH versus age-matched peers [5], predictive of the menopausal transition among WWH [4], and associated with oxidative stress, immune activation, and subclinical CVD in perimenopausal WWH [5, 11, 12]. Specifically, WWH with reduced ovarian reserve (undetectable AMH) had a higher prevalence of coronary atherosclerotic plaque than premenopausal WWH with detectable AMH [12]. These data suggest that innovative tool development, perhaps including measurement of AMH or related hormonal and/or immunologic biomarkers, may be clinically useful in screening pre-/perimenopausal WWH at risk of early reproductive and natural aging and premature NACM development.

Our analysis was limited by a moderately small sample size and participant self-report of menopausal status, which limited our ability to accurately determine if participants were experiencing menopause versus irregular periods due to other medical conditions. Strengths included our focus on a critically understudied topic in HIV science, use of data from a well-curated women's cohort, and evaluation of menopausal status on overall NACM burden. In conclusion, our results suggest that disparate NACM burden among WWH may concentrate in the pre- and perimenopausal phases and therefore the optimal timing to initiate NACM risk assessment and

intervention may precede menopause in these women. Larger, prospective studies among WWH well characterized by menopause status are needed to better understand how HIV affects this reproductive transition, including timing, severity, risk factors, and implications for aging-related comorbidity development, so that timely NACM identification and risk modification can be offered to those uniquely at risk.

Notes

Acknowledgments. The authors thank the WIHS participants who contributed time and data to this study. In addition, they are grateful to the WIHS for their support and data utilization. Finally, they thank the WIHS site co-investigators for serving as site liaisons for data collaboration.

Disclaimer. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH).

Financial support. Data in this manuscript were collected by the Women's Interagency HIV Study, now the MACS/WIHS Combined Cohort Study (MWCCS). MWCCS (Principal Investigators): Atlanta Clinical Research Site (CRS) (Ighoverha Ofotokun, Anandi Sheth, and Gina Wingood), U01-HL146241; Baltimore CRS (Todd Brown and Joseph Margolick), U01-HL146201; Bronx CRS (Kathryn Anastos and Anjali Sharma), U01-HL146204; Brooklyn CRS (Deborah Gustafson and Tracey Wilson), U01-HL146202; Data Analysis and Coordination Center (Gypsyamber D'Souza, Stephen Gange, and Elizabeth Golub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Chicago-Northwestern CRS (Steven Wolinsky), U01-HL146240; Northern California CRS (Bradley Aouizerat, Jennifer Price, and Phyllis Tien), U01-HL146242; Los Angeles CRS (Roger Detels), U01-HL146333; Metropolitan Washington CRS (Seble Kassaye and Daniel Merenstein), U01-HL146205; Miami CRS (Maria Alcaide, Margaret Fischl, and Deborah Jones), U01-HL146203; Pittsburgh CRS (Jeremy Martinson and Charles Rinaldo), U01-HL146208; UAB-MS CRS (Mirjam-Colette Kempf, Jodie Dionne Odom, and Deborah Konkle-Parker), U01-HL146192; UNC CRS (Adaora Adimora), U01-HL146194. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Allergy And Infectious Diseases (NIAID), National Institute of Neurological Disorders And Stroke (NINDS), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute

of Nursing Research (NINR), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). MWCCS data collection is also supported by UL1-TR000004 (University of California San Francisco [UCSF] Clinical & Translational Science Alliance [CTSA]), P30-AI-050409 (Emory Center for AIDS Research [CFAR]), P30-AI-050410 (University of North Carolina [UNC] CFAR), and P30-AI-027767 (University of Alabama [UAB] CFAR). This work was also supported by the Emory Specialized Center of Research Excellence (SCORE) on Sex Differences to I.O. (award number U54AG062334). L. F. C. is also supported by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health through the Georgia CTSA (award numbers UL1TR002378 and KL2-TL1TR002381) and the Program for Retaining, Supporting, and Elevating Early-career Researchers at Emory (PeRSEVERE) from Emory School of Medicine, a gift from the Doris Duke Charitable Foundation.

Potential conflicts of interest. A. A. reports funding for research provided to their institution from Merck and Gilead; consulting fees paid to the author from Merck and Gilead; a role as a member of the Infectious Diseases Society Board of Directors and as a member of International AIDS Society Governing Council. K. A. reports 3 grants from the National Institutes of Health (NIH) paid to their institution and unrelated to this work; support attending meetings and/or travel in the form of grants paid to their institution from the NIH. M.-C. K. reports support unrelated to this work from the NIH and paid to their institution. S. K. reports support unrelated to this work from the NIH and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Integritas Communications. M. A. F. reports support unrelated to this work from the NHLBI NIH. S. N. reports payments to their institution unrelated to this work from Gilead Sciences and AbbVie Pharmaceuticals; consulting fees paid to the author from Pardes Biosciences, Theratechnologies, and Silverback Therapeutics; participation on an Advisory Board for Vir Biotechnology, a Data Safety and Monitoring Board (DSMB) for Personal Health Insights, Inc, and an Event Adjudication Committee for Bristol-Myers Squibb/PRA; and 2866 stocks with options up to 5500 from Vir Biotechnology. I. O. reports grants or contracts from Merck unrelated to this work for Study 022 and Study 024 and a \$4500 payment made to the author for consulting from Accordant (a CVS Caremark Company). F. J. P. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from ViiV, Gilead, Merck, and Janssen. P. C. T. reports grants or contracts unrelated to this work and paid to their institution from Merck. T. N. T. reports the following grants unrelated to this manuscript: Public Health Solutions (PHS) 21-BHO-364 Building Equity: Intervening Together for Health (BE InTo Health) for Black and/or Hispanic/Latino Older People with HIV (ages 50 and older) (project focuses on geriatric assessments in primary HIV care; sexual health

is a minor focus; author is project director) and a PRIDE Special Research Project (SRP) award (R25HL105444-09; G. Jean-Louis, Principal Investigator [PI]) Adapting Cognitive Behavioral Therapy for Menopause-Associated Insomnia (CBT-MI) for Peri- and Post-menopausal Women with HIV (adapt and tailor CBT-MI for women with HIV with complex health needs and pilot test the feasibility of implementing this intervention within a primary HIV care setting; the author is PI). T. N. T. also reports consulting fees as a Qualitative Data Consultant for Dr. Anjali Sharma at Albert Einstein College of Medicine (project focuses on older adults with HIV and sexual health is a focus).

All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2019. HIV Surveillance Report 2021;32. <https://www.cdc.gov/hiv/pdf/group/gender/women/cdc-hiv-women.pdf> [Accessed March 16, 2022].
- El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. *Circulation* 2020; 142:e506–32.
- Tariq S, Anderson J, Burns F, et al. The menopause transition in women living with HIV: current evidence and future avenues of research. *J Virus Erad* 2016; 2:114–6.
- Scherzer R, Greenblatt RM, Merhi ZO, et al. Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. *Am J Obstet Gynecol* 2017; 216:46.e1–e11.
- Merlini E, Greenblatt RM, Merhi ZO, et al. Predictors of low ovarian reserve in cART-treated women living with HIV. *Medicine (Baltimore)* 2021; 100:e27157.
- Huaman MA, Fichtenbaum CJ. Bearing the burden of non-AIDS comorbidities: this is what women aging with HIV look like. *Clin Infect Dis* 2021; 72:1312–3.
- Collins LF, Sheth AN, Mehta CC, et al. The prevalence and burden of non-AIDS comorbidities among women living with or at risk for human immunodeficiency virus infection in the United States. *Clin Infect Dis* 2021; 72: 1301–11.
- Collins LF, Sheth AN, Mehta CC, et al. Incident non-AIDS comorbidity burden among women with or at risk for human immunodeficiency virus in the United States. *Clin Infect Dis* 2021; 73:e2059–69.
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop+10: addressing the unfinished agenda of staging reproductive aging. *Menopause* 2012; 19:387–95.
- Abelman R, Tien PC. The reproductive transition: effects on viral replication, immune activation, and metabolism in women with HIV infection. *Curr HIV/AIDS Rep* 2022; 19:133–9.
- Peters BA, Xue X, Sheira LA, et al. Menopause is associated with immune activation in women with HIV. *J Infect Dis* 2022; 225:295–305.
- Looby SE, Fitch KV, Srinivasa S, et al. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. *AIDS* 2016; 30:383–93.